UFP Technologies (UFPT) Q3 2026 Earnings Call Transcript
UFP Technologies (UFPT) reported Q3 2026 sales up 11.6%, with organic growth at 11.1%. Gross margin improved to 29.4% from 27.7% last year. Adjusted EPS was $2.88, up significantly. The company is investing in growth, including acquisitions like CI Medical, and expanding credit facilities. AJR operations are behind schedule but expected to improve in 2027. Management remains optimistic about long-term growth and shareholder value.
How this was made
The 30-second read
Why it matters
The earnings beat and strategic moves suggest a bullish outlook, but execution risks remain.
Market read
Strong earnings and acquisition news could drive UFPT stock higher, with sector ripple effects.
What to watch
Potential delays in AJR transfer to Dominican Republic and execution risk on new capacity could temper upside.
Background
UFP Technologies provided its Q3 2026 earnings call, highlighting growth, margin expansion, acquisition activity, and operational updates.
Ticker impact
Q3 2026 earnings disclosed 11.6% sales growth, margin expansion to 29.4% and $2.88 EPS, new acquisition of CI Medical and capacity expansions.
upward pressure as the market prices in better-than-expected earnings and growth outlook
Revenue and EPS beat, margin expansion, and strategic acquisitions signal continued growth, prompting buyers.
Market effects
Positive for medical device plastics and contract manufacturing sector, may lift peers.
U.S. industrial and healthcare manufacturing outlook strengthened.
Limited to sectors tied to medical device supply chains.
Counterpoint
If margin improvements are temporary and integration costs of CI Medical rise, the stock could face pressure.
Key entities
- companyUFP Technologies
Medical device and contract manufacturing firm reporting Q3 2026 results.
- companyCI Medical
Acquired niche medical device printing business.
